503b bulk list
Semaglutide Exclusion Drains 30% Profit From Small Pharmacies
Small pharmacies will see profit margins tighten as the nation’s $1 trillion prescription-drug spend fuels higher GLP-1 prices.(USA Today)The FDA’s move to pull semaglutide from the 503B bulk list adds a new layer of cost pressure for compounding operations that rely on low-margin ingredient sourcing. Medical